Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome

Pediatric Nephrology

Volumn 17, Issue 12, 2002, Pages 1053-1058

  Siegler, Richard L ^a   Pysher, Theodore J ^a   Tesh, Vernon L ^b   Denkers, Nathaniel D ^a   Taylor, Fletcher B ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Anti coagulation; Escherichia coli; Heparinization; HUS; Shiga toxin

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; FIBRIN; LOW MOLECULAR WEIGHT HEPARIN; SHIGA TOXIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BABOON; BLOOD CLOTTING; CLINICAL OBSERVATION; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; GLOMERULUS CAPILLARY; HEMOLYTIC UREMIC SYNDROME; HEPARINIZATION; INHIBITION KINETICS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; RISK MANAGEMENT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; VASCULAR ENDOTHELIUM;

ANEMIA, HEMOLYTIC; ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; HEPARIN; KIDNEY; KIDNEY FUNCTION TESTS; MICROSCOPY, FLUORESCENCE; PAPIO; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; SHIGA TOXIN; THROMBOCYTOPENIA;

EID: 12244253702     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-002-1002-3     Document Type: Article

References (33)

1. Monnens L, van Aken W, de Jong M (1982) "Active" intravascular coagulation in the epidemic form of hemolytic-uremic syndrome. Clin Nephrol 17:284-287
2. Vitacco M, Sanchez Avalos J, Gianantonio CA (1973) Heparin therapy in the hemolytic-uremic syndrome. J Pediatr 83:271-275
3. Van Damme-Lombaerts R, Proesmans W, Van Damme B, Eeckels R, Binda ki Muaka P, Mercieca V, Vlietinck R, Vermylen J (1988) Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 113:913-918
4. Van Geet C, Proesmans W, Arnout J, Vermylen J, Declerck PJ (1998) Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 54:1324-1330
5. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346:23-32
6. Levin M, Barratt JM (1984) Haemolytic uraemic syndrome. Arch Dis Child 59:397-400
7. Cimolai N, Carter JE, Morrison BJ (1990) Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 116:589-592
8. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE (1994) A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Nephrol 42:85-89
9. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 26:1930-1936
10. Taylor FB Jr, Tesh VL, DeBault L, Li A, Chang ACK, Kosanke SD, Pysher TJ, Siegler RL (1999) Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154:1285-1299
11. Siegler RL, Pysher TJ, Tesh VL, Taylor FB Jr (2001) Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 12:1458-1467
12. Tesh VL, Ramegowda B, Samuel JE (1994) Purified Shigalike toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 62:5085-5094
13. Appiani AC, Edefonti A, Bettinelli A, Cossu MM, Paracchini ML, Rossi E (1982) The relationship between plasma levels of the factor VIII complex and platelet release products (β-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 17:195-199
14. Nevard CH, Jurd KM, Lane DA, Philippou H, Haycock GB, Hunt BJ (1997) Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 78:1450-1455
15. Badami KG, Srivastava RN, Kumar R, Saraya AK (1987) Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome. Acta Paediatr Scand 76:919-922
16. Bergstein JM, Riley M, Bang NU (1992) Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 327:755-759
17. Menzel D, Levi M, Dooijewaard G, Peters M, ten Cate JW (1994) Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood. Ann Hematol 68:43-48
18. Louise CB, Obrig TG (1994) Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvas Res 47:377-387
19. Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM, On behalf of the British Association for Pediatric Nephrology (1997) Renal histopathology in fatal cases of diarrhoea- associated haemolytic uraemic syndrome. Pediatr Nephrol 11:556-559
20. Richardson SE, Karmali MA, Becker LE, Smith CR (1988) The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 19:1102-1108
21. Argyle JC, Hogg RJ, Pysher TJ, Silva FG, Siegler RL (1990) A clinicopathological study of 24 children with hemolytic uremic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 4:52-58
22. Diekmann L (1980) Treatment of the hemolytic-uremic syndrome with streptokinase and heparin [author's translation]. Klin Padiatr 192:430-435
23. Loirat C, Beaufils F, Sonsino E, Habib R, Andre JL, Broyer M, Costil J, Gagnadoux MF, Guyot C, Mathieu H (1982) Urokinase (UK) treatment for hemolytic uremic syndrome (HUS) in childhood: a multicenter controlled trial from the French Society of Pediatric Nephrology [Abstract]. Int J Pediatr Nephrol 3:46
24. Jones RW, Morris MC, Maisey MN, Saxton HM, Chantler C (1981) Endarterial urokinase in childhood hemolytic uremic syndrome. Kidney Int 20:723-727
25. Siegler RL (1995) Hemolytic uremic syndrome in children. Curr Opin Pediatr 7:159-163
26. Ostroff SM, Kobayashi JM, Lewis JH (1989) Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 262:355-359
27. Milford DV, Staten J, MacGreggor I, Dawes J, Taylor CM, Hill FG (1991) Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen. Nephrol Dial Transplant 6:232-237
28. Robson WL, Fick GH, Wilson PC (1988) Prognostic factors in typical postdiarrhea hemolytic-uremic syndrome. Child Nephrol Urol 9:203-207
29. Siegler R, Obrig T, Pysher T, Tesh V, Denkers N, Taylor J, FB (2001) The comparative virulence of Shiga toxin 1 and Shiga toxin 2 in a primate model of hemolytic uremic syndrome (HUS) [Abstract]. J Am Soc Nephrol 12:182A
30. Tesh V (1998) Cytokine response to Shiga toxins. In: Kaper JB, O'Brien AD (eds) Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society of Microbiology, Washington D.C. pp 226-235
31. Obrig TG, Moran TP, Brown JE (1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244:287-294
32. Esmon CT (2001) Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 29:S48-S51; discussion S51-S52
33. Prisco D, Falciani M, Antonucci E, Gensini GF (2001) Hirudins for prophylaxis and treatment of venous thromboembolism. Semin Thromb Hemost 27:543-550